Background: In recent years, attention has been drawn to the therapeutic usefulness of bromocriptine in the effective management of insulin resistance diabetes mellitus. Materials and Methods: The present study evaluates the effects of the oral treatments with 10 mg/kg bromocriptine in fixed combinations with 1 mg/kg glibenclamide, 20 mg/kg metformin and glibenclamide/metformin combination on body weight, blood glucose, lipids and cardiovascular risk profile in dexamethasone-induced hyperglycemic male Wistar rats for 30 days. The effects of these drug combinations on OGTT of the treated rats were also evaluated. Results: Repeated daily dexamethasone injection for 30 days caused significant increases in the average body weight, blood glucose, triglycerides, total cholesterol, LDL-c, VLDL-c and cardiovascular risk indices in the treated male Albino Wistar rats. However, these increases were significantly attenuated in rats orally pretreated with bromocriptine and its various combinations. In addition, bromocriptine and its combinations significantly improved OGTT in the treated rats. Conclusions: Overall, results of this study suggest that the antihyperglycaemic, antihyperlipidaemic and cardioprotective effects of the fixed-dose drug combinations were possibly mediated via improved glucose tolerance mechanism.